Navigation Links
SmartGene, Inc. Enters Collaboration with Virco Lab, Inc. to Enhance HIV Genotyping and Resistance Interpretation Services in US
Date:4/20/2009

RALEIGH, N.C., April 20 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced a marketing and distribution collaboration with Virco Lab, Inc., to help US laboratories manage, analyze, and derive maximum benefit from their HIV sequences. Virco will market SmartGene, Inc.'s secure, Web-based service module, SmartGene(R) HIV, which is a unique, integrated, data management solution encompassing various interpretation algorithms, multiple genetic targets and cumulative resistance reporting.

The SmartGene HIV platform will allow laboratories using both SmartGene, Inc. and Virco services to send an order for interpretation of sequence data by Virco directly out of the SmartGene HIV module and then store the resulting virco(R)TYPE HIV-1 resistance reports within their SmartGene database.

"HIV clinicians and laboratorians understand the importance of longitudinal data to resistance assessment; they value the insight gained from reinterpreting sequences with updated algorithms and comparing results derived from different algorithms; they are interested in analyzing new genetic targets, such as Integrase and Envelope. SmartGene HIV exquisitely meets these needs," said David Ellis, President of SmartGene, Inc. "We have made excellent progress introducing our modules supporting bacterial and fungal identification by sequence analysis. As we expand the deployment of our services for virology in the US, we are delighted to enter this collaboration with Virco, a long-standing market leader for resistance testing and interpretation in the HIV field."

About SmartGene, Inc.

SmartGene, Inc. is the North American subsidiary of SmartGene GmbH, a privately-held company based in Zug, Switzerland, which provides its services worldwide. SmartGene provides web-based suites of functionality to facilitate sequence-based analysis for a variety of clinical, medical research, and veterinary applications. Constant updates to reference data and interpretive algorithms keep SmartGene's customers in step with evolving science and improve the accuracy of sequence interpretation. SmartGene's integrated services increase the speed to result for sequence-based diagnostics and improve workflow in the laboratory. Current modules from SmartGene include Bacteria, Fungi, HIV, HCV, MLST, Influenza, and HLA typing. Future applications will address human genetics as well as food and environmental pathogens. Discover more at www.smartgene.com.


'/>"/>
SOURCE SmartGene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/23/2016)... 2016 ReportsnReports.com adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):